Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
复制标题
DOI：
10.1038/clpt.2011.287
复制
发表时间：
2012-02-01
影响因子：
6.7
通讯作者：
Skaar, T. C.
中科院分区：
文献类型：
--
作者：
Crews, K. R.;Gaedigk, A.;Skaar, T. C.
可待因通过肝脏细胞色素P450 2D6(细胞色素P450 2D6)对阿片类强效激动剂吗啡产生生物活性，因此，可待因作为镇痛剂的有效性和安全性受细胞色素P450 2D6基因多态性的影响。对于代谢能力较差的患者，可待因几乎没有疗效，而在超速代谢的患者中，吗啡中毒的风险更高。本指南(在http://www.pharmgkb.org)定期更新)的目的是提供与解释CYP2D6基因测试结果相关的信息，以指导可待因的剂量。
Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are governed by CYP2D6 polymorphisms. Codeine has little therapeutic effect in patients who are CYP2D6 poor metabolizers, whereas the risk of morphine toxicity is higher in ultrarapid metabolizers. The purpose of this guideline (periodically updated at http://www.pharmgkb.org) is to provide information relating to the interpretation of CYP2D6 genotype test results to guide the dosing of codeine.